<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35319791</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>NR1D1 downregulation in astrocytes induces a phenotype that is detrimental to cocultured motor neurons.</ArticleTitle><Pagination><StartPage>e22262</StartPage><MedlinePgn>e22262</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e22262</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.202101275R</ELocationID><Abstract><AbstractText>Nuclear receptor subfamily 1&#xa0;group D member 1 (NR1D1, also known as Rev-erb&#x3b1;) is a nuclear transcription factor that is part of the molecular clock encoding circadian rhythms and may link daily rhythms with metabolism and inflammation. NR1D1, unlike most nuclear receptors, lacks a ligand-dependent activation function domain 2 and is a constitutive transcriptional repressor. Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease, caused by the progressive degeneration of motor neurons in the spinal cord, brain stem, and motor cortex. Approximately 10%-20% of familial ALS is caused by a toxic gain-of-function induced by mutations of the Cu/Zn superoxide dismutase (SOD1). Dysregulated clock and clock-controlled gene expression occur in multiple tissues from mutant hSOD1-linked ALS mouse models. Here we explore NR1D1 dysregulation in the spinal cord of ALS mouse models and its consequences on astrocyte-motor neuron interaction. NR1D1 protein and mRNA expression are significantly downregulated in the spinal cord of symptomatic mice expressing mutant hSOD1, while no changes were observed in age-matched animals overexpressing wild-type hSOD1. In addition, NR1D1 downregulation in primary astrocyte cultures induces a pro-inflammatory phenotype and decreases the survival of cocultured motor neurons. NR1D1 orchestrates the cross talk between physiological pathways identified to be disrupted in ALS (e.g., metabolism, inflammation, redox homeostasis, and circadian rhythms) and we observed that downregulation of NR1D1 alters astrocyte-motor neuron interaction. Our results suggest that NR1D1 could be a potential therapeutic target to prevent astrocyte-mediated motor neuron toxicity in ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Killoy</LastName><ForeName>Kelby M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Wisconsin-Madison, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harlan</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Biomedical Sciences Training Program, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pehar</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education Clinical Center, Veterans Affairs Medical Center, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas</LastName><ForeName>Marcelo R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Wisconsin-Madison, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS089640</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS102599</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498262">Nr1d1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056953">Nuclear Receptor Subfamily 1, Group D, Member 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056953" MajorTopicYN="N">Nuclear Receptor Subfamily 1, Group D, Member 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NR1D1</Keyword><Keyword MajorTopicYN="N">Rev-erb&#x3b1;</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">motor neurons</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35319791</ArticleId><ArticleId IdType="mid">NIHMS1817398</ArticleId><ArticleId IdType="pmc">PMC9223394</ArticleId><ArticleId IdType="doi">10.1096/fj.202101275R</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raghuram S, Stayrook KR, Huang P, et al. Identification of heme as the ligand for the orphan nuclear receptors REV&#x2010;ERBalpha and REV&#x2010;ERBbeta. Nat Struct Mol Biol. 2007;14:1207&#x2010;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743565</ArticleId><ArticleId IdType="pubmed">18037887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin L, Wu N, Curtin JC, et al. Rev&#x2010;erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science. 2007;318:1786&#x2010;1789.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006707</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud JP, Harris JM, Downes M, Burke LJ, Muscat GE. Structure&#x2010;function analysis of the Rev&#x2010;erbA and RVR ligand&#x2010;binding domains reveals a large hydrophobic surface that mediates corepressor binding and a ligand cavity occupied by side chains. Mol Endocrinol. 2000;14:700&#x2010;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">10809233</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding HP, Lazar MA. The orphan receptor Rev&#x2010;ErbA alpha activates transcription via a novel response element. Mol Cell Biol. 1993;13:3113&#x2010;3121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC359704</ArticleId><ArticleId IdType="pubmed">8474464</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding HP, Lazar MA. The monomer&#x2010;binding orphan receptor Rev&#x2010;Erb represses transcription as a dimer on a novel direct repeat. Mol Cell Biol. 1995;15:4791&#x2010;4802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230723</ArticleId><ArticleId IdType="pubmed">7651396</ArticleId></ArticleIdList></Reference><Reference><Citation>Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol. 2001;63:647&#x2010;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181971</ArticleId></ArticleIdList></Reference><Reference><Citation>Preitner N, Damiola F, Lopez&#x2010;Molina L, et al. The orphan nuclear receptor REV&#x2010;ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251&#x2010;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda HR, Chen W, Adachi A, et al. A transcription factor response element for gene expression during circadian night. Nature. 2002;418:534&#x2010;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">12152080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato TK, Panda S, Miraglia LJ, et al. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron. 2004;43:527&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312651</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Zhao X, Hatori M, et al. Regulation of circadian behaviour and metabolism by REV&#x2010;ERB&#x2010;alpha and REV&#x2010;ERB&#x2010;beta. Nature. 2012;485:123&#x2010;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367514</ArticleId><ArticleId IdType="pubmed">22460952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JE, Blaikley J, Beesley S, et al. The nuclear receptor REV&#x2010;ERBalpha mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc Natl Acad Sci USA. 2012;109:582&#x2010;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258648</ArticleId><ArticleId IdType="pubmed">22184247</ArticleId></ArticleIdList></Reference><Reference><Citation>Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV&#x2010;ERB agonists. Nature. 2012;485:62&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343186</ArticleId><ArticleId IdType="pubmed">22460951</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin P, Dimitry JM, Sheehan PW, et al. Circadian clock protein Rev&#x2010;erbalpha regulates neuroinflammation. Proc Natl Acad Sci USA. 2019;116:5102&#x2010;5107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421453</ArticleId><ArticleId IdType="pubmed">30792350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother. 2017;18:735&#x2010;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2010;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, Fiano V. Astrogliosis in ALS: possible interpretations according to pathogenetic hypotheses. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:22&#x2010;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15204020</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeito LH, Pehar M, Cassina P, et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev. 2004;47:263&#x2010;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572176</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson JA. Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics. 2010;7:471&#x2010;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967019</ArticleId><ArticleId IdType="pubmed">20880509</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253&#x2010;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Sun Y, Ling SC, et al. Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1&#x2010;mediated ALS. Proc Natl Acad Sci USA. 2015;112:E6993&#x2010;E7002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687558</ArticleId><ArticleId IdType="pubmed">26621731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Pehar M, Cassina P, Beckman JS, Barbeito L. Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR&#x2010;dependent motor neuron apoptosis. J Neurochem. 2006;97:687&#x2010;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524372</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS&#x2010;linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615&#x2010;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non&#x2010;cell autonomous effect of glia on motor neurons in an embryonic stem cell&#x2010;based ALS model. Nat Neurosci. 2007;10:608&#x2010;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet&#x2010;Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29:824&#x2010;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K, Ferraiuolo L, Miranda CJ, et al. Direct conversion of patient fibroblasts demonstrates non&#x2010;cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci USA. 2014;111:829&#x2010;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditsworth D, Maldonado M, McAlonis&#x2010;Downes M, et al. Mutant TDP&#x2010;43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:907&#x2010;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427168</ArticleId><ArticleId IdType="pubmed">28357566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kia A, McAvoy K, Krishnamurthy K, Trotti D, Pasinelli P. Astrocytes expressing ALS&#x2010;linked mutant FUS induce motor neuron death through release of tumor necrosis factor&#x2010;alpha. Glia. 2018;66:1016&#x2010;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873384</ArticleId><ArticleId IdType="pubmed">29380416</ArticleId></ArticleIdList></Reference><Reference><Citation>Killoy KM, Pehar M, Harlan BA, Vargas MR. Altered expression of clock and clock&#x2010;controlled genes in a hSOD1&#x2010;linked amyotrophic lateral sclerosis mouse model. FASEB J. 2021;35:e21343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963346</ArticleId><ArticleId IdType="pubmed">33508151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Xu G, Gonzales V, et al. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper&#x2010;binding site. Neurobiol Dis. 2002;10:128&#x2010;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">12127151</ArticleId></ArticleIdList></Reference><Reference><Citation>Saneto RP, Vellis JD . Neuronal and glial cells: cell culture of the central nervous system. In Neurochemistry: A Practical Approach; 1987:27&#x2010;63.</Citation></Reference><Reference><Citation>Harlan BA, Pehar M, Sharma DR, Beeson G, Beeson CC, Vargas MR. Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis&#x2010;linked mutant superoxide dismutase 1 (SOD1). J Biol Chem. 2016;291:10836&#x2010;10846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865928</ArticleId><ArticleId IdType="pubmed">27002158</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Killoy KM, Pehar M, Liu L, Auwerx J, Vargas MR. Evaluation of the NAD(+) biosynthetic pathway in ALS patients and effect of modulating NAD(+) levels in hSOD1&#x2010;linked ALS mouse models. Exp Neurol. 2020;327:113219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089832</ArticleId><ArticleId IdType="pubmed">32014438</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Pehar M, Killoy KM, Vargas MR. Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS&#x2010;linked mutant SOD1. FASEB J. 2019;33:7084&#x2010;7091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6529338</ArticleId><ArticleId IdType="pubmed">30841754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Lin Y, Yuan X, Li F, Guo L, Wu B. REV&#x2010;ERBalpha integrates colon clock with experimental colitis through regulation of NF&#x2010;kappaB/NLRP3 axis. Nat Commun. 2018;9:4246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6185905</ArticleId><ArticleId IdType="pubmed">30315268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell A, Chappuis S, Schmutz I, et al. The nuclear receptor REV&#x2010;ERBalpha regulates Fabp7 and modulates adult hippocampal neurogenesis. PLoS One. 2014;9:e99883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4059695</ArticleId><ArticleId IdType="pubmed">24932636</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheyden WM, Fang B, Flores CC, Jager J, Gerstner JR. The transcriptional repressor Rev&#x2010;erbalpha regulates circadian expression of the astrocyte Fabp7 mRNA. Curr Res Neurobiol. 2021;2:100009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162199</ArticleId><ArticleId IdType="pubmed">34056625</ArticleId></ArticleIdList></Reference><Reference><Citation>Killoy KM, Harlan BA, Pehar M, Vargas MR. FABP7 upregulation induces a neurotoxic phenotype in astrocytes. Glia. 2020;68:2693&#x2010;2704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7573932</ArticleId><ArticleId IdType="pubmed">32619303</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Qian K, Chen W, et al. Human&#x2010;derived neural progenitors functionally replace astrocytes in adult mice. J Clin Investig. 2015;125:1033&#x2010;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362241</ArticleId><ArticleId IdType="pubmed">25642771</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian K, Huang H, Peterson A, et al. Sporadic ALS astrocytes induce neuronal degeneration in vivo. Stem Cell Reports. 2017;8:843&#x2010;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390239</ArticleId><ArticleId IdType="pubmed">28366455</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11:251&#x2010;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Gutmann DH, Roos RP. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum Mol Genet. 2011;20:286&#x2010;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">20962037</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci. 2008;28:13574&#x2010;13581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Harlan BA, Killoy KM, Vargas MR. Role and therapeutic potential of astrocytes in amyotrophic lateral sclerosis. Curr Pharm Des. 2017;23:5010&#x2010;5021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740017</ArticleId><ArticleId IdType="pubmed">28641533</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer AS, Koszka K, Kiskinis E, Suzuki N, Davis&#x2010;Dusenbery BN, Eggan K. Genetic validation of a therapeutic target in a mouse model of ALS. Sci Transl Med. 2014;6:248ra104.</Citation><ArticleIdList><ArticleId IdType="pubmed">25100738</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E, Cassina A, Martinez&#x2010;Palma L, et al. Neuroprotective effects of the mitochondria&#x2010;targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med. 2014;70:204&#x2010;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">24582549</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S, Miranda CJ, Braun L, et al. Major histocompatibility complex class I molecules protect motor neurons from astrocyte&#x2010;induced toxicity in amyotrophic lateral sclerosis. Nat Med. 2016;22:397&#x2010;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823173</ArticleId><ArticleId IdType="pubmed">26928464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner PD, Stephenson DT, Wright S. Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. J Neuropathol Exp Neurol. 1991;50:263&#x2010;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">2022968</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D, Kato T, Kushner PD. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J Neurosci Res. 1994;38:336&#x2010;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">7523689</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly SA, Roedica J, Nagy D, et al. Motor neuron&#x2010;astrocyte interactions and levels of Cu, Zn superoxide dismutase in sporadic amyotrophic lateral sclerosis. Exp Neurol. 1995;131:203&#x2010;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7895821</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci. 1996;139(suppl):27&#x2010;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS&#x2010;linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14:1105&#x2010;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Becher MW, Lee MK, et al. ALS&#x2010;linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1&#x2010;containing inclusions. Neuron. 1997;18:327&#x2010;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998;23:249&#x2010;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Aoki M, Miyoshi I, et al. Rats expressing human cytosolic copper&#x2010;zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci. 2001;21:9246&#x2010;9254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763929</ArticleId><ArticleId IdType="pubmed">11717358</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant&#x2010;mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA. 2002;99:1604&#x2010;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling SC, Huelga SC, et al. ALS&#x2010;linked TDP&#x2010;43 mutations produce aberrant RNA splicing and adult&#x2010;onset motor neuron disease without aggregation or loss of nuclear TDP&#x2010;43. Proc Natl Acad Sci USA. 2013;110:E736&#x2010;E745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupre N, et al. Deregulation of TDP&#x2010;43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB&#x2010;mediated pathogenic pathways. J Exp Med. 2011;208:2429&#x2010;2447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Kim DE, Griffin P, et al. Inhibition of REV&#x2010;ERBs stimulates microglial amyloid&#x2010;beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer's disease. Aging Cell. 2020;19:e13078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996949</ArticleId><ArticleId IdType="pubmed">31800167</ArticleId></ArticleIdList></Reference><Reference><Citation>Schibler U, Gotic I, Saini C, et al. Clock&#x2010;talk: interactions between central and peripheral circadian oscillators in mammals. Cold Spring Harb Symp Quant Biol. 2015;80:223&#x2010;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">26683231</ArticleId></ArticleIdList></Reference><Reference><Citation>Maury E, Hong HK, Bass J. Circadian disruption in the pathogenesis of metabolic syndrome. Diabet Metab. 2014;40:338&#x2010;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">24433933</ArticleId></ArticleIdList></Reference><Reference><Citation>Asher G, Sassone&#x2010;Corsi P. Time for food: the intimate interplay between nutrition, metabolism, and the circadian clock. Cell. 2015;161:84&#x2010;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">25815987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass J. Circadian topology of metabolism. Nature. 2012;491:348&#x2010;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">23151577</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubblefield JJ, Terrien J, Green CB. Nocturnin: at the crossroads of clocks and metabolism. Trend Endocrinol Metab. 2012;23:326&#x2010;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389576</ArticleId><ArticleId IdType="pubmed">22608110</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2010;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Larkin JR, Claridge TD, Talbot K, Sibson NR, Turner MR. The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2015;16:456&#x2010;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4720042</ArticleId><ArticleId IdType="pubmed">26121274</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53:1059&#x2010;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Pehar M, Cassina P, et al. Fibroblast growth factor&#x2010;1 induces heme oxygenase&#x2010;1 via nuclear factor erythroid 2&#x2010;related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J Biol Chem. 2005;280:25571&#x2010;25579.</Citation><ArticleIdList><ArticleId IdType="pubmed">15870071</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2010;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, Desport JC, Clavelou P, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256:1236&#x2010;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, Bruneteau G, Gordon PH, et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:166&#x2010;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson DA, Johnson JA. Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS&#x2010;linked hSOD1(G93A) mice model. Neurobiol Dis. 2011;43:543&#x2010;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139005</ArticleId><ArticleId IdType="pubmed">21600285</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, Cudkowicz ME, Brown MV, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012;13:110&#x2010;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">22117131</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo V, Wark PA, Jenab M, et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology. 2013;80:829&#x2010;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598455</ArticleId><ArticleId IdType="pubmed">23390184</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Burton NC, Kutzke J, et al. Absence of Nrf2 or its selective overexpression in neurons and muscle does not affect survival in ALS&#x2010;linked mutant hSOD1 mouse models. PLoS One. 2013;8:e56625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572065</ArticleId><ArticleId IdType="pubmed">23418589</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly EJ, Wang H, Weisskopf MG, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:205&#x2010;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615420</ArticleId><ArticleId IdType="pubmed">23134505</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Beeson G, Beeson CC, Johnson JA, Vargas MR. Mitochondria&#x2010;targeted catalase reverts the neurotoxicity of hSOD1G(9)(3)A astrocytes without extending the survival of ALS&#x2010;linked mutant hSOD1 mice. PLoS One. 2014;9:e103438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108402</ArticleId><ArticleId IdType="pubmed">25054289</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, Seelen M, van Doormaal PT, et al. Effect of presymptomatic body mass index and consumption of fat and alcohol on amyotrophic lateral sclerosis. JAMA Neurol. 2015;72:1155&#x2010;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">26280944</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Arcuti S, Jesus P, et al. Population&#x2010;based evidence that survival in amyotrophic lateral sclerosis is related to weight loss at diagnosis. Neurodegener Dis. 2016;16:225&#x2010;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">26866503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tso CF, Simon T, Greenlaw AC, Puri T, Mieda M, Herzog ED. Astrocytes regulate daily rhythms in the suprachiasmatic nucleus and behavior. Curr Biol. 2017;27:1055&#x2010;1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5380592</ArticleId><ArticleId IdType="pubmed">28343966</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancaccio M, Patton AP, Chesham JE, Maywood ES, Hastings MH. Astrocytes control circadian timekeeping in the suprachiasmatic nucleus via glutamatergic signaling. Neuron. 2017;93:1420&#x2010;1435.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5376383</ArticleId><ArticleId IdType="pubmed">28285822</ArticleId></ArticleIdList></Reference><Reference><Citation>Barca&#x2010;Mayo O, Pons&#x2010;Espinal M, Follert P, Armirotti A, Berdondini L, De Pietri Tonelli D. Astrocyte deletion of Bmal1 alters daily locomotor activity and cognitive functions via GABA signalling. Nat Commun. 2017;8:14336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5309809</ArticleId><ArticleId IdType="pubmed">28186121</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee CA, Lananna BV, Musiek ES. Circadian regulation of astrocyte function: implications for Alzheimer's disease. Cell Mol Life Sci. 2020;77:1049&#x2010;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098845</ArticleId><ArticleId IdType="pubmed">31578625</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>